(2023)
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study.
ANTICANCER RESEARCH.
43,
9
(2023)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
LANCET.
401,
10391
(2023)
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY.
16,
(2022)
The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer.
CANCERS.
14,
19
(2022)
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY.
-,
-
(2022)
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Clinical Oncology.
34,
8
(2022)
Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.
ANNALS OF SURGICAL ONCOLOGY.
-,
-
(2022)
Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study.
EUROPEAN JOURNAL OF CANCER.
163,
-
(2022)
HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer.
FRONTIERS IN ONCOLOGY.
12,
(2021)
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT.
20,
(2021)
Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population- based cohort study.
EUROPEAN JOURNAL OF CANCER.
155,
(2021)
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
ESMO OPEN.
6,
2
(2021)
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.
ANNALS OF ONCOLOGY.
-,
-
(2021)
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
JOURNAL OF CLINICAL ONCOLOGY.
-,
-
(2021)
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.
IN VIVO.
35,
1
(2021)
Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer.
JOURNAL OF CANCER.
12,
2
(2020)
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
12,
(2020)
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
GENOME MEDICINE.
12,
1
(2020)
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors.
EXPERT OPINION ON INVESTIGATIONAL DRUGS.
29,
9
(2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY.
38,
27
단행본
(2012)
위암표준진료권고안.
동아사.
공동
특허/프로그램
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
스페인
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
독일
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS}.
11849123.2.
20180808.
폴란드
학술회의논문
(2012)
Heat shock protein-90 (Hsp-90) inhibitor, 17-AAG blocks transforming growth factor (TGF)-β1 induced epithelial-mesenchymal transition (EMT) in A549 cells.
European Journal of Cancer Suppl 6.
아일랜드
(2011)
Pazopanib, a novel multi-targeted kinase inhibitor shows potent in vitro antitumor activity in gastric cancer cell lines harboring FGFR2 amplification, which is a potential therapeutic target in gastric cancer..
Molecular Targets and Cancer Therapeutics.
미국
(2011)
KRAS mutation predicts unfavorable clinical outcomes in pancreatic ductal adenocarcinoma patients who were treated with first-line gemcitabine-based chemotherapy..
AACR 102nd Anuual Meeting.
미국
(2010)
Hepatobiliary/Pancreas Cancer.
2010 ASCO Review & Highlight.
대한민국
(2010)
A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum..
2010 ASCO Annual Meeting.
미국
(2010)
Analysis of prognostic factors of pediatric-type sarcomas in adult patients..
2010 ASCO Annual Meeting.
미국
(2010)
Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy..
2010 ASCO Annual Meeting.
미국
(2010)
Molecular profiling of pulmonary pleomorphic carcinoma: Implications for targeted treatment of a rare lung malignancy..
2010 ASCO Annual Meeting.
미국
(2010)
Management of Pediatric Sarcomas in Adults.
2010년 제12차 Consensus Conference: Sarcoma/GU&GY Cancer.
대한민국
(2010)
Functional profiling of signal transduction pathway proteins in gastric cancer patients.
AACR Meeting Abstracts.
미국
(2010)
Clinical Significance of FGFR2 amplification in gastric cancer.
AACR Meeting Abstracts.
미국
(2010)
A randomized phase II study of combination chemotherapy with epirubicin, cisplatin, and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer (AGC)..
2010 Gastrointestinal Cancers Symposium.
미국
(2010)
A retrospective analysis of stage IB gastric cancer (GC) patients who underwent D2 gastrectomy with or without adjuvant chemoradiotherapy..
2010 Gastrointestinal Cancers Symposium.
미국
(2009)
MET amplification by qPCR predicts poor outcome in gastric cancer: a novel prognostic marker and a potential therapeutic target.
European Journal of Cancer Supplements.
독일
(2009)
Prognostic model to predict outcomes in pancreatic adenocarcimoma patients who received surgical resection with curative intent.
European Journal of Cancer Supplements.
독일
(2009)
Impact of MET Amplification on Gastric Cancer: A Novel Prognostic Marker and A Potential Therapeutic Target..
100th AACR annual meeting.
미국
(2009)
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
2009 Gastrointestinal Cancers Symposium.
미국
(2008)
A Phase I/II Trial of docetaxel and oxaliplatin in patienes with advanced gastric cancer..
ASCO.
미국
(2006)
Phase II Study of Capecitabine and Cisplatin as First -Line Chemotherapy in Patients with Advanced Esophageal Cancer..
Annals of Oncology.
튀르키예
(2006)
Phase II Study of Capecitabine and Cisplatin in Advanced Biliary Tract Cancer.
Cancer Research and Treatment.
대한민국
